期刊
NATURE REVIEWS DRUG DISCOVERY
卷 15, 期 10, 页码 699-718出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd.2016.120
关键词
-
资金
- Cancer Research UK
- Experimental Cancer Medicine Centre
- National Institute for Health Research Biomedical Research Centre
- MRC [G0502133] Funding Source: UKRI
- Cancer Research UK [11566] Funding Source: researchfish
- Medical Research Council [G0502133] Funding Source: researchfish
Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses considerable therapeutic challenges. Recent genetic and technological advances have provided insights into prostate cancer biology and have enabled the identification of novel drug targets and potent molecularly targeted therapeutics for this disease. In this article, we review recent advances in prostate cancer target identification for drug discovery and discuss their promise and associated challenges. We review the evolving therapeutic landscape of CRPC and discuss issues associated with precision medicine as well as challenges encountered with immunotherapy for this disease. Finally, we envision the future management of CRPC, highlighting the use of circulating biomarkers and modern clinical trial designs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据